# Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients

> **NCT04616209** · PHASE1,PHASE2 · RECRUITING · sponsor: **Precision Biotech Taiwan Corp.** · enrollment: 24 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** donor-derived NK cell infusion

## Key facts

- **NCT ID:** NCT04616209
- **Lead sponsor:** Precision Biotech Taiwan Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-15
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04616209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04616209, "Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04616209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*